Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pixantrone vs. Physician's Choice in Relapsed Aggressive NHL (PIX301)
NCT00088530Phase 3Completed
- Sponsor
- CTI BioPharma Corp.
- Start
- Jul 2004
- Primary completion
- Feb 2010
- Countries
- 20
01
Overview
Phase 3, randomised, open-label trial of pixantrone in non-Hodgkin lymphoma (NHL) (2 arms), sponsored by CTI BioPharma Corp. Primary endpoint: Complete Response and Complete Response Unconfirmed at 6 months. Started Jul 2004; status: completed.
02
Drugs
pixantrone
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00088530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00088530.